Global Lung Cancer Screening Market Shows Strong Growth Momentum
The lung cancer screening market was valued at USD 3.66 billion in 2024 and is projected to reach USD 7.44 billion by 2032, expanding at a CAGR of 9.32% during the forecast period of 2025–2032. This robust growth reflects a structural shift in global oncology care toward preventive screening and early diagnosis, particularly among high-risk populations such as chronic smokers and older adults.
Lung cancer remains the most lethal cancer globally, largely because it is often diagnosed at advanced stages. As a result, governments, healthcare systems, and private stakeholders are prioritizing systematic screening initiatives. The increasing penetration of low-dose computed tomography, combined with technological advances such as AI-based image analysis, is significantly strengthening the Lung Cancer Screening Market outlook.
Explore Emerging Market Insights: Request a Sample Report Now: https://www.snsinsider.com/sample-request/3392
Market Revenue Analysis Highlights Rising Preventive Healthcare Spend
Rising healthcare expenditure on early detection programs is a major contributor to Lung Cancer Screening Market revenue growth. National screening guidelines, insurance reimbursement policies, and public awareness campaigns have encouraged higher screening participation rates. In parallel, mobile screening units and community-based initiatives are extending access beyond traditional hospital settings.
In the United States alone, the Lung Cancer Screening Market was valued at USD 1.12 billion in 2024 and is expected to reach USD 2.21 billion by 2032, growing at a CAGR of 8.89%. The U.S. continues to lead due to strong reimbursement support, USPSTF recommendations, and Medicare coverage for LDCT screening.
AI and Imaging Innovations Reshape Screening Workflows
Technological innovation is a defining force shaping the Lung Cancer Screening Market. AI-powered imaging tools are improving diagnostic accuracy, reducing false positives, and enabling radiologists to manage increasing scan volumes efficiently. AstraZeneca and Qure’s recent report on processing more than 5 million AI-powered chest X-rays across 20+ countries underscores the scalability of AI in real-world screening workflows.
Clinical evidence further supports this transition. Studies published in Nature Oncology indicate that AI-augmented LDCT tools deliver sensitivity of 94.6% and specificity of 93.6%, reinforcing confidence among clinicians and payers. At the 2025 ATS International Conference, deep-learning models demonstrated strong predictive capability, even among never-smokers, signaling a move toward personalized risk-based screening.
High Disease Burden Continues to Drive Screening Demand
The high global burden of lung cancer remains the most powerful driver of the Lung Cancer Screening Market. In 2020, approximately 2.2 million new lung cancer cases and 1.8 million deaths were reported worldwide. By 2035, lung cancer-related deaths are expected to approach 3 million if early detection measures are not scaled effectively.
In the U.S., the American Cancer Society estimates over 2 million new cancer diagnoses in 2025, with lung cancer accounting for nearly 11–12% of cases. While incidence and mortality rates have shown modest declines between 2018 and 2022, these improvements highlight the tangible impact of prevention and screening strategies, reinforcing further investment in screening infrastructure.
Cost Barriers Remain a Key Market Restraint
Despite positive growth trends, high screening costs remain a significant restraint for the Lung Cancer Screening Market. Advanced LDCT systems, biomarker-based tests, and AI platforms require substantial capital investment, skilled personnel, and supporting infrastructure. In low- and middle-income countries, limited healthcare budgets and inadequate insurance coverage restrict widespread screening adoption.
Additionally, follow-up diagnostics after initial screenings often increase out-of-pocket expenses for patients, further limiting participation. Addressing affordability through public funding, partnerships, and mobile screening programs will be critical for sustained market expansion.
LDCT Continues to Dominate Screening Modalities
By test modality, low-dose computed tomography accounted for 61.25% of the Lung Cancer Screening Market share in 2024. LDCT’s superior sensitivity in detecting small lung nodules, combined with lower radiation exposure compared to conventional CT, has made it the gold standard for screening high-risk populations. Its inclusion in national guidelines across the U.S. and Europe further reinforces its dominance.
In contrast, biomarker-based tests are expected to grow at the fastest CAGR over the forecast period. These non-invasive approaches, including liquid biopsies, align closely with precision medicine trends and offer promising opportunities to complement imaging-based screening.
NSCLC Screening Remains Central to Market Expansion
By cancer type, non-small cell lung cancer represented approximately 84.15% of the Lung Cancer Screening Market in 2024. NSCLC’s slower progression compared to small cell lung cancer allows greater opportunity for early detection through LDCT screening. As clinical practice guidelines emphasize NSCLC-focused screening, demand continues to rise.
NSCLC is also anticipated to be the fastest-growing segment, supported by advances in molecular diagnostics, targeted therapies, and biomarker integration. These developments are reinforcing the role of screening as a gateway to precision oncology.
Expanding Screening Across Age Groups and Care Settings
Adults aged 60–69 years dominated the Lung Cancer Screening Market in 2024 due to higher cumulative exposure to risk factors and established screening eligibility criteria. However, the 50–59 age group is emerging as the fastest-growing segment, reflecting evolving guidelines and increasing awareness of early screening benefits.
Hospitals remain the leading end users, supported by advanced imaging infrastructure and reimbursement eligibility. At the same time, mobile screening units, NGOs, and community health programs are gaining traction, particularly in underserved regions, contributing to faster market penetration.
High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report: https://www.snsinsider.com/reports/lung-cancer-screening-market-3392
Regional Insights Highlight Asia Pacific Growth Potential
North America accounted for around 40.3% of the Lung Cancer Screening Market in 2024, driven by early LDCT adoption, strong reimbursement frameworks, and advanced healthcare systems. Europe follows closely, supported by expanding national screening programs and preventive healthcare initiatives.
Asia Pacific is projected to register the highest growth rate, with a CAGR of approximately 9.94%. Rising lung cancer incidence, increasing healthcare spending, AI adoption, and government-led mass screening initiatives in China, Japan, and South Korea are key contributors to this momentum.
Key Players
GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Samsung Medison Co., Ltd., Carestream Health, Shimadzu Corporation, Vuno Inc., Zebra Medical Vision, Qure.ai, Aidoc, Riverain Technologies, Lunit Inc., Roche Diagnostics, Illumina, Inc., Guardant Health, Exact Sciences Corporation, Bio-Rad Laboratories, CT Screening International
Future Outlook
The future of the Lung Cancer Screening Market is closely tied to technological convergence and policy support. AI-driven diagnostics, liquid biopsies, and mobile screening platforms are expected to redefine accessibility and accuracy. As governments intensify preventive healthcare strategies and reimbursement expands, screening uptake is likely to increase across both developed and emerging economies.
Conclusion
The Lung Cancer Screening Market is entering a transformative phase marked by strong growth, technological innovation, and expanding global awareness. While cost barriers remain, advances in AI, LDCT, and community-based screening models are steadily improving early detection rates. With lung cancer continuing to pose a significant global health challenge, sustained investment in screening infrastructure will remain central to improving outcomes and market expansion.
Frequently Asked Questions
What is the current valuation of the Lung Cancer Screening Market?
The Lung Cancer Screening Market was valued at USD 3.66 billion in 2024.
What will be the market value by 2032?
By 2032, the Lung Cancer Screening Market is expected to reach USD 7.44 billion.
Which segment dominates the market?
Low-dose computed tomography currently dominates the market due to its effectiveness in early lung cancer detection.
Which region shows the highest growth potential?
Asia Pacific is projected to witness the fastest growth due to rising lung cancer incidence and expanding screening programs.
What factors are driving market growth?
Key drivers include increasing lung cancer prevalence, aging populations, adoption of LDCT, and integration of AI-based screening technologies.
Other Trending Reports
